Skip to main content
Advertising

Originally published Wednesday, May 8, 2013 at 9:48 AM

  • Share:
           
  • Comments (0)
  • Print

Merck: FDA reviewing its ragweed allergy therapy

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

WHITEHOUSE STATION, N.J. —

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.

Merck's latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.

It could become an alternative to months of uncomfortable allergy shots. Both methods gradually desensitize the immune system to the substance triggering the allergic reaction.

In March, the Whitehouse Station, N.J., company said the FDA was reviewing its application for an immunotherapy tablet for grass pollen allergies.

Merck expects FDA rulings on both still-unnamed treatments in 2014's first half.

News where, when and how you want it

Email Icon

Subscribe today!

Subscribe today!

Get 8 weeks of digital access to The Seattle Times for $1

Advertising

Advertising


Advertising
The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►